SG11202103972SA - Neurological disease treatment with zilucoplan - Google Patents

Neurological disease treatment with zilucoplan

Info

Publication number
SG11202103972SA
SG11202103972SA SG11202103972SA SG11202103972SA SG11202103972SA SG 11202103972S A SG11202103972S A SG 11202103972SA SG 11202103972S A SG11202103972S A SG 11202103972SA SG 11202103972S A SG11202103972S A SG 11202103972SA SG 11202103972S A SG11202103972S A SG 11202103972SA
Authority
SG
Singapore
Prior art keywords
zilucoplan
neurological disease
disease treatment
neurological
treatment
Prior art date
Application number
SG11202103972SA
Inventor
Petra Duda
Ramin Farzaneh-Far
Zhong Ma
Nanqun Zhu
Evan Thackaberry
Alonso Ricardo
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of SG11202103972SA publication Critical patent/SG11202103972SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4848Monitoring or testing the effects of treatment, e.g. of medication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/32Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321Means for protection against accidental injuries by used needles
    • A61M5/322Retractable needles, i.e. disconnected from and withdrawn into the syringe barrel by the piston
    • A61M5/3234Fully automatic needle retraction, i.e. in which triggering of the needle does not require a deliberate action by the user
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
SG11202103972SA 2018-10-22 2019-10-22 Neurological disease treatment with zilucoplan SG11202103972SA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862748659P 2018-10-22 2018-10-22
US201862777524P 2018-12-10 2018-12-10
US201962815575P 2019-03-08 2019-03-08
US201962837974P 2019-04-24 2019-04-24
US201962844388P 2019-05-07 2019-05-07
US201962899864P 2019-09-13 2019-09-13
PCT/US2019/057316 WO2020086506A1 (en) 2018-10-22 2019-10-22 Neurological disease treatment with zilucoplan

Publications (1)

Publication Number Publication Date
SG11202103972SA true SG11202103972SA (en) 2021-05-28

Family

ID=68696508

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103972SA SG11202103972SA (en) 2018-10-22 2019-10-22 Neurological disease treatment with zilucoplan

Country Status (13)

Country Link
US (1) US20220133841A1 (en)
EP (1) EP3870221A1 (en)
JP (1) JP2022508952A (en)
KR (1) KR20210080390A (en)
CN (1) CN113226368A (en)
AU (1) AU2019365804A1 (en)
BR (1) BR112021007083A2 (en)
CA (1) CA3115828A1 (en)
MA (1) MA53986A (en)
MX (1) MX2021004366A (en)
SG (1) SG11202103972SA (en)
TW (1) TW202034943A (en)
WO (1) WO2020086506A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019011053A2 (en) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc complement activity modulators
BR112022002522A2 (en) 2019-09-12 2022-08-16 Ra Pharmaceuticals Inc TREATMENT OF NEUROLOGICAL DISEASES WITH COMPLEMENT INHIBITORS
WO2023215586A1 (en) 2022-05-05 2023-11-09 UCB Biopharma SRL Treatment of myasthenia gravis with zilucoplan
WO2023215587A1 (en) 2022-05-05 2023-11-09 UCB Biopharma SRL Treatment of myasthenia gravis with zilucoplan

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007293013B2 (en) * 2006-09-05 2013-06-27 Alexion Pharmaceuticals, Inc. Method and compositions for the treatment of antibody mediated neuropathies
WO2010025510A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
EP3628680B1 (en) * 2014-06-12 2021-09-08 RA Pharmaceuticals, Inc. Modulation of complement activity
RS62630B9 (en) 2015-01-28 2022-04-29 Ra Pharmaceuticals Inc Modulators of complement activity

Also Published As

Publication number Publication date
US20220133841A1 (en) 2022-05-05
EP3870221A1 (en) 2021-09-01
CN113226368A (en) 2021-08-06
TW202034943A (en) 2020-10-01
BR112021007083A2 (en) 2021-08-03
WO2020086506A1 (en) 2020-04-30
KR20210080390A (en) 2021-06-30
MX2021004366A (en) 2021-08-16
CA3115828A1 (en) 2020-04-30
JP2022508952A (en) 2022-01-19
AU2019365804A1 (en) 2021-05-20
MA53986A (en) 2022-01-26

Similar Documents

Publication Publication Date Title
SG11202103972SA (en) Neurological disease treatment with zilucoplan
IL263188B (en) Treatment for parkinson's disease
GB201813876D0 (en) Treatment
IL267818A (en) Methods for the treatment of neurological disorders
IL255506A (en) Method for the treatment of neurological disease
GB201721287D0 (en) Treatment for inflammatory disease
GB201620611D0 (en) Treatment of neurological diseases
IL281792A (en) Treatment methods
GB201800546D0 (en) Treatment
IL281839A (en) Treatment methods
IL271322A (en) Non-invasive neural interface
IL282361A (en) Treatment of neurological diseases
IL270788A (en) Sulfonylurea compounds in the treatment of disease associated with uv-induced damage
GB201914296D0 (en) Treatment
GB201715763D0 (en) Treatment of neurological disease
GB201811629D0 (en) Venous disease
SG11202101196TA (en) Behavioural treatment
GB201814905D0 (en) Treatment
GB201811911D0 (en) Treatment of disease
GB201811912D0 (en) Treatment of disease
GB201810974D0 (en) Treatment of disease
GB201913294D0 (en) Neurological modification therapy
ZA201807944B (en) Treatment for parkinson's disease
GB201912760D0 (en) Treatment
GB201912365D0 (en) Treatment